Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
8 participants
INTERVENTIONAL
2008-10-31
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ghrelin Decreases Insulin Sensitivity
NCT00512525
Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET
NCT01185119
Local Metabolic Effects of Ghrelin in Skeletal Muscle and Adipose Tissue
NCT01595373
Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects
NCT03139305
Hepatic Metabolic Changes in Response to Glucagon Infusion
NCT03526445
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ghrelin
Ghrelin
Solvent, cont. infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ghrelin
Solvent, cont. infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Written informed consent
3. Non-smoker
Exclusion Criteria
2. Any use of medications (excl. paracetamol)
3. Present or previous malignancy
4. Alcohol dependency
5. Allergy to any trial medication
18 Years
60 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aarhus University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jens Otto L. Jorgensen, MD
Role: STUDY_DIRECTOR
Medical Department M, Aarhus University Horpital, Denmark
Esben T Vestergaard, PhD
Role: PRINCIPAL_INVESTIGATOR
Medical Department M, Aarhus University Hospital, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University Hospital
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M-2007008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.